During the past decade, Princess Margaret Cancer Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Princess Margaret Cancer Research" are "Acute Myeloid Leukemia (AML)" (1 trials), "Higher-Risk Myelodysplastic Syndrome (HR-MDS)" (1 trials), "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" (1 trials), "Metastatic Colorectal Cancer (mCRC)" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Princess Margaret Cancer Research" in a lesser frequency.

Most popular intervention types in "Princess Margaret Cancer Research" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (2 trials), "ASTX727" (1 trials), "Bortezomib" (1 trials), "KPT-8602" (1 trials) and "Selinexor" (1 trials). Other intervention names were less common.

The vast majority of trials in "Princess Margaret Cancer Research" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Princess Margaret Cancer Research". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Princess Margaret Cancer Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Princess Margaret Cancer Research, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".